Viyash Scientific Investor Day 2026 Strategic Presentation

The document is an intimation and submission of a presentation for "Viyash Investor Day – 2026", a scheduled investor engagement event.
The event was scheduled for June 25, 2026, in Mumbai, as per the company's previous intimation dated June 17, 2026.
The stated purpose of the event was to present the company's strategy and platform following the merger of Viyash Life Sciences and Sequent Scientific.
The presentation was made available on the company's website at www.viyash.com.
The document is a regulatory filing submitted pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Management participants featured in the presentation include Dr. Haribabu Bodepudi, MD & Group CEO, who has 30 years of pharmaceutical industry experience and was previously CEO of Viyash Life Sciences and held leadership roles at Mylan.
The document does not contain any specific compliance language stating that no unpublished price sensitive information (UPSI) will be shared.

The enclosed Investor Day presentation provided a comprehensive business overview:

Company Journey and Integration:

Detailed the merger between Viyash Life Sciences (founded Feb 2019 by Dr. Haribabu Bodepudi) and Sequent Scientific (originated 1985, rebranded 2013).
Viyash Life Sciences growth included acquisitions of Vindhya Pharma, Vandana Life Sciences, Mylan's API units, Symed Labs, and Appco Pharma LLC.
Sequent Scientific established Alivira animal health brand and expanded globally with USFDA veterinary API approvals.

Manufacturing Capabilities:

API Manufacturing: 9 manufacturing units with detailed capabilities and regulatory approvals (USFDA, EU-GMP, PMDA, TGA, KFDA, WHO-GMP, COFEPRIS, ANVISA).
Formulations Manufacturing: Global footprint across Spain, Turkey, Brazil, India, and US with capabilities in multiple dosage forms including oral liquids, injectables, pre-filled syringes, and high potent formulations.

R&D Capabilities:

API R&D: 225+ scientists in Hyderabad, Telangana, focusing on complex APIs including high-potent (OEB 4/5) & cytotoxic compounds.
Formulation R&D - Human Health: 60+ members in India for OSD and Onco-Cytotoxic generics plus complex pharmaceuticals.
Formulation R&D - Animal Health: 55+ members across India, Spain, Turkey for generic & complex dosage forms.
Patent Portfolio: 185+ cumulative patents filed to date; 60 patents filed since FY23 with 57 regulatory approvals and 14 patents granted.

Business Portfolio Snapshot:

Animal Formulations: 10+ commercial companion animal products with 66+ in pipeline; 130+ commercial farm animal products with 21+ in pipeline.
Human API: 60 commercial products with 63 in pipeline (including 22 first-to-file launches).
Human Formulations: 30+ commercial molecules with 24 in pipeline (including 11 first-to-file launches).
Market Presence: Operations across 150+ countries.

Growth Aspirations and Drivers:

Companion Animals: Target $150-200Mn revenue; aim to become top 10 global animal health player; recent acquisition of Bio For Life in Italy provides 85-product portfolio and 85% vet clinic coverage.
Farm Animals: Geo-extension of 25+ products; entry into new markets (Vietnam, Australia, Canada, Africa, Latam); 20+ new products in pipeline.
API + CDMO: Target to triple business with >25% CAGR over next 5 years.
Human Formulations: Focus on complex generics and first-to-file opportunities.

Synergies Achieved: Product and cost optimization, network synergies across markets and customers, corporate and management integration.

The document includes the full Investor Day presentation as an attachment.
The announcement itself does not disclose specific financial data or performance metrics, focusing instead on strategic positioning and capabilities.
The presentation contains forward-looking statements and disclaimers regarding future performance, noting dependence on economic conditions, regulatory changes, market demand, and other risk factors.